| A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. | |
| | |
MedLine Citation:
|
PMID: 18787469 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The currently available tumour markers used in the management of patients with colorectal metastases are of limited value. Tumour M2-pyruvate kinase (TuM2-PK), a tumour-associated isoenzyme of pyruvate kinase, is elevated in patients with gastrointestinal cancer. This study has measured TuM2-PK levels in patients before and after resection of colorectal liver metastases (CLM). MATERIALS AND METHODS: Fifty patients with CLM and no local residual disease had TuM2-PK levels measured before liver resection. In 20 patients, TuM2-PK levels were repeated at 2 weeks, 5 weeks and 5 months after resection. Plasma levels were analysed by enzyme-linked immunosorbent assay (ScheBo, Giessen, Germany). Carcinoembryonic antigen (CEA) and CA19-9 levels were measured at the same time periods by electrochemiluminescence immunoassay. CEA, CA19-9 and TuM2-PK levels were compared with the tumour number, volume, differentiation and stage. Cut-off values used for TuM2-PK, CEA and CA19-9 were 15 IU/ml, 10 ng/ml and 39 IU/ml, respectively. RESULTS: TuM2-PK was elevated in 68%, CEA in 62% and CA19-9 in 40% of patients with CLM. TuM2-PK+CEA was elevated in 88% and TuM2-PK+CA19-9 in 78% of patients. A significant correlation was observed between tumour volume and CEA (r=0.34, P<0.05) and CA19-9 (r=0.49, P<0.005). TuM2-PK levels did not show a significant correlation with tumour differentiation, volume or the number of metastases. At 2 weeks after liver resection, CEA and CA19-9 levels had decreased to normal value in 73 and 67% of patients, respectively, but TuM2-PK remained elevated in all patients. At 5 weeks, TuM2-PK, CEA and CA19-9 levels decreased to normal in 64, 93 and 70% of patients, respectively, and at 5 months levels were normal in 58, 92 and 67%. CONCLUSION: Plasma TuM2-PK is commonly elevated in patients with CLM. Levels do not correlate with tumour volume, number or differentiation. Levels remain elevated after liver resection, the cause of which requires further investigation. |
| | |
Authors:
|
Yogesh Kumar; Inigo R Pinedo; Niteen Tapuria; Abigail Zabron; Brian R Davidson |
Related Documents
:
|
2842159 - Early detection of response in small cell bronchogenic carcinoma by changes in serum co... 18258649 - Biochemical markers of myocardial injury in the pericardial fluid of patients undergoin... 9631749 - Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a... 17549069 - Open prostatectomy for benign prostate hyperplasia: short-term outcome in 3000 consecut... 19631319 - Comparison of the clinical value of ca 19-9 versus ca 125 for the diagnosis of endometr... 10221859 - Apoptosis and nuclear shapes in benign prostate hyperplasia and prostate adenocarcinoma... 3899089 - Vaginal delivery following caesarean section. 22177369 - Kawasaki disease and henoch-schönlein purpura - 10 years' experience of childhood vasc... 19374089 - Mechanisms of oedema formation: the minor role of hypoalbuminaemia. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 20 ISSN: 1473-5687 ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-12 Completed Date: 2008-12-15 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 1006-11 Citation Subset: IM |
Affiliation:
|
University Department of Surgery, HPB and Liver Transplant Unit, Royal Free Hospital, Royal Free and University College Medical School, University College London, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged CA-19-9 Antigen / blood* Carcinoembryonic Antigen / blood* Case-Control Studies Chemiluminescent Measurements / methods Colorectal Neoplasms / pathology, surgery Enzyme-Linked Immunosorbent Assay / methods Female Humans Immunoassay / methods Liver Neoplasms / pathology, secondary*, surgery Male Middle Aged Neoplasm Staging Postoperative Period Pyruvate Kinase / blood* Tumor Markers, Biological / blood* |
| Chemical | |
Reg. No./Substance:
|
0/CA-19-9 Antigen; 0/Carcinoembryonic Antigen; 0/Tumor Markers, Biological; EC 2.7.1.40/Pyruvate Kinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Declining frequency of liver enzyme abnormalities with statins: experience from general practice in ...
Next Document: Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II ...